docetaxel + cyclophosphamide + paclitaxel + trastuzumab

TC-H + paclitaxel + trastuzumab refers to the therapeutic regimens evaluated in a Phase 3 randomized clinical trial (NCT03705429) for patients with lower-risk HER2-positive early-stage breast cancer. The study compares two standard-of-care adjuvant treatments: the TC-H regimen (comprising docetaxel, cyclophosphamide, and trastuzumab) and the P-H regimen (comprising weekly paclitaxel and trastuzumab). Trastuzumab is a humanized monoclonal antibody that targets the HER2 protein to inhibit tumor cell proliferation. Docetaxel and paclitaxel are taxane chemotherapy agents that stabilize microtubules, preventing cell division, while cyclophosphamide is an alkylating agent that damages DNA. The trial, led by the London Health Sciences Centre Research Institute, focuses on assessing the feasibility of a pragmatic trial design, toxicity profiles, and cost-effectiveness in a real-world clinical setting.

Other names

TC-H + paclitaxel + trastuzumabTC-H vs P-Hdocetaxel + cyclophosphamide + trastuzumab and paclitaxel + trastuzumab